PYC Therapeutics (ASX:PYC) advanced work on its three investigational drug candidates in clinical development during the quarter ended Dec. 31, 2025, with a fourth expected to enter human trials in the first half of 2027, according to a Friday filing with the Australian bourse.

The company aims to complete the single ascending dose study in patients prior to starting a multiple ascending dose study to establish clinical proof of concept for its drug candidate in polycystic kidney disease, the filing said.

In its autosomal dominant optic atrophy program, the company is also working to establish clinical proof of concept through ongoing repeat-dose studies.

Additionally, the company anticipates completing a Type D meeting with the US Food and Drug Administration for a registrational trial design, which will support a new drug application in retinitis pigmentosa type 11 in the first quarter of the year, per the filing.

Shares fell 1% in afternoon trade on Friday.